Exchange: NASDAQ·Updated 07:30 PM EDT
CLYM logo

CLYM Climb Bio Inc.

$14.40
$0.49
(3.25%)
Today
Closed $14.57
$0.1681
(1.15%)
After Hours
Reported EarningsAug 6
Mkt Cap$836.85M
Vol840,930.00

About CLYM

Climb Bio, Inc. operates as a clinical-stage biotechnology company. The firm develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wellesley Hills, MA.
42

Bearish Sentiment

How do you feel about CLYM?

Advertisement|Remove ads.